Jesper Jørgensen

Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries

Jesper Jørgensen, Eve Hanna, Panos Kefalas · Journal of Market Access & Health Policy · 2020 · 115 citations · Full text

Public Affairs, Health Policy, Pharmacoeconomics +16

Reimbursement of licensed cell and gene therapies across the major European healthcare markets

Jesper Jørgensen, Panos Kefalas · Journal of Market Access & Health Policy · 2015 · 50 citations · Full text

Pharmacy, Health Policy, Pharmaceutical Policy +17

Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test

Jesper Jørgensen, Panos Kefalas · Journal of Market Access & Health Policy · 2017 · 47 citations · Full text

Pharmacy, Health Policy, Pharmacoeconomics +17

Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching

Jesper Jørgensen, Laura Mungapen, Panos Kefalas · Journal of Market Access & Health Policy · 2019 · 19 citations · Full text

Pharmacy, Pharmacoeconomics, Gene Therapy +15

Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy

Panos Kefalas, Jesper Jørgensen, N. Merryfield et al. · Journal of Market Access & Health Policy · 2018 · 18 citations · Full text

Public Affairs, Health Policy, Oncology +17